Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.85 USD

45.85
11,933,398

+0.45 (0.99%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $45.75 -0.10 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Company News for April 28, 2017

by Zacks Equity Research

Companies in the News are: F,LUV,UNP,BMY

    Arpita Dutt headshot

    Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

    by Arpita Dutt

    Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

      Zacks Equity Research

      Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

      by Zacks Equity Research

      Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

        Zacks Equity Research

        Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY

        by Zacks Equity Research

        Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.

          Zacks Equity Research

          Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

          by Zacks Equity Research

          Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

            Zacks Equity Research

            Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

              Sweta Killa headshot

              Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

              by Sweta Killa

              Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

                Arpita Dutt headshot

                3 Key Factors to Look Out for in Biogen's Q1 Results

                by Arpita Dutt

                With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

                  by Arpita Dutt

                  Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

                    Zacks Equity Research

                    Is J&J's Pharma Sales Slowdown a Warning for Other Players?

                    by Zacks Equity Research

                    Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

                      Zacks Equity Research

                      Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

                      by Zacks Equity Research

                      Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).

                        Zacks Equity Research

                        Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

                        by Zacks Equity Research

                        Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

                          Zacks Equity Research

                          5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates

                          by Zacks Equity Research

                          2017 is expected to be a strong year for drug stocks.

                            Zacks Equity Research

                            Biogen to License Alzheimer Candidate from Bristol-Myers

                            by Zacks Equity Research

                            Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

                              Zacks Equity Research

                              J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?

                              by Zacks Equity Research

                              We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops

                                by Arpita Dutt

                                Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.

                                  Zacks Equity Research

                                  Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo

                                  by Zacks Equity Research

                                  Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.

                                    Zacks Equity Research

                                    AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

                                    by Zacks Equity Research

                                    AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

                                      Zacks Equity Research

                                      Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

                                      by Zacks Equity Research

                                      We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

                                        Zacks Equity Research

                                        Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA

                                        by Zacks Equity Research

                                        Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.

                                          Zacks Equity Research

                                          5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

                                          by Zacks Equity Research

                                          Lily carries a Zacks Rank #2 (Buy).

                                            Zacks Equity Research

                                            Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo

                                            by Zacks Equity Research

                                            Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.

                                              Zacks Equity Research

                                              Bristol-Myers (BMY), Incyte to Advance Clinical Program

                                              by Zacks Equity Research

                                              Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

                                                Zacks Equity Research

                                                Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage

                                                by Zacks Equity Research

                                                Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.

                                                  Zacks Equity Research

                                                  Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion

                                                  by Zacks Equity Research

                                                  Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.